CancerDrs Find care

Liver Cancer clinical trials in District of Columbia

9 actively recruiting liver cancer trials at 1 site across District of Columbia.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Evaluating Novel Therapies in ctDNA Positive GI Cancers

This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall bladder adenocar…

Sponsor: Georgetown University
NCT ID: NCT05482516
Sites in District of Columbia:
  • Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
  • Medstar Washington Hospital Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-p…

Sponsor: Genentech, Inc.
NCT ID: NCT06096779
Sites in District of Columbia:
  • Washington DC VA Medical Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.

Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in District of Columbia:
  • Washington Cancer Institute at MedStar Washington Hospital Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

FOG-001 in Locally Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.

Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in District of Columbia:
  • Johns Hopkins University, Sibley Memorial Hospital — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepato…

Sponsor: Tvardi Therapeutics, Incorporated
NCT ID: NCT05440708
Sites in District of Columbia:
  • Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that has come b…

Sponsor: Children's Oncology Group
NCT ID: NCT06620302
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing…

Sponsor: Hoffmann-La Roche
NCT ID: NCT04524871
Sites in District of Columbia:
  • Georgetown University Medical Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Recruiting Academic/Other

Cancer Experience Registry (CER) for Cancer Patients and Caregivers

The Cancer Experience Registry®: An Online Survey Research Study to Understand the Experiences of Those Impacted By a Cancer Diagnosis. The Registry is a web-based platform to distribute cross-sectional and longitudinal surveys. Study surv…

Sponsor: Cancer Support Community, Research and Training Institute, Philadelphia
NCT ID: NCT02333604
Sites in District of Columbia:
  • Cancer Support Community Research & Training Institute — Washington D.C., District of Columbia
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20